Wanlin Biopharmaceutical Technology

Wanlin Biopharmaceutical is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of novel small molecule drugs for oncology and autoimmune diseases. The company utilizes a proprietary drug discovery platform to identify and optimize candidates targeting key biological pathways such as KRAS and JAK. Its lead candidate, WL-101, is a potent and selective KRAS G12C inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors, including non-small cell lung cancer. Wanlin Biopharmaceutical is backed by leading venture capital firms and is committed to delivering transformative therapies to patients globally through its R&D center in the Suzhou Industrial Park.